Patent Daily RSS
Twitter Guna
- Access the Bayer’s appeal - bit.ly/Lj9RMP 6 days ago
- Bayer seeks to stay the operation of the CL order - bit.ly/JBAlIS 6 days ago
- USPTO Offers Patent Applicants Option to Supplement Disclosure of Prior Art After Paying Issue Fee - bit.ly/Ju5BYd 1 week ago
- Piramal Healthcare to buy US firm to boost R&D - bit.ly/MiVA1V 1 week ago
- Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert - bit.ly/JHsWnw 1 week ago
- Biotech body criticises Bayer on cancer drug - bit.ly/J5DEpF 1 week ago
- India drugs inquiry could prompt new U.S. scrutiny - reut.rs/JDVT5y 1 week ago
- Cipla breached patent rights by slashing cancer drug price: Bayer - bit.ly/JyCBys 2 weeks ago
- No pharma application pending for compulsory licence: Govt - bit.ly/K3OUQy 2 weeks ago
- India’s patent protection regime to be key issue in talks with US - bit.ly/Jfhluh 2 weeks ago
Monthly Archives: October 2011
Breach of agreement-Onyx Vs Bayer-Sorafenib derivative
This is about breach of contract/collaborative agreement between onyx and bayer. [Press release] Recently Onyx and Bayer announced settlement agreement regarding the drug called “Regorafenib”(BAY73-4506). Regorafenib is structurally similar to sorafenib except a Fluoro substitution on sorafenib moiety. Sorafenib Regorafenib … Continue reading
New Patentscope interface
Wipo recently announced that New Patentscope interface will replace old patentscope. This new patentscope comes certainly with some additional features. WIPO call it as “New customizable search interface“ Some obvious improvements are: Easily switch over interface between Search interfaces and … Continue reading